1887

Abstract

Recombinant simian varicella viruses (rSVVs) were engineered to express respiratory syncytial virus (RSV) antigens. The RSV surface glycoprotein G and second matrix protein M2 (22k) genes were cloned into the SVV genome, and recombinant viruses were characterized and . rSVVs were also engineered to express the membrane-anchored or secreted forms of the RSV-G protein as well as an RSV G lacking its chemokine mimicry motif (CX3C), which may have different effects on priming the host immune response. The RSV genes were efficiently expressed in rSVV/RSV-infected Vero cells as RSV-G and -M2 transcripts were detected by RT-PCR, and RSV antigens were detected by immunofluorescence and immunoblot assays. The rSVVs replicated efficiently in Vero cell culture. Rhesus macaques immunized with rSVV/RSV-G and rSVV/RSV-M2 vaccines produced antibody responses to SVV and RSV antigens. The results demonstrate that recombinant varicella viruses are suitable vectors for the expression of RSV antigens and may represent a novel vaccine strategy for immunization against both pathogens.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83453-0
2008-03-01
2020-01-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/3/741.html?itemId=/content/journal/jgv/10.1099/vir.0.83453-0&mimeType=html&fmt=ahah

References

  1. Arnold, R., Konig, B., Werchau, H. & Konig, W. ( 2004; ). Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 330, 384–397.[CrossRef]
    [Google Scholar]
  2. Arvin, A. M., Mallory, S. & Moffat, J. F. ( 1999; ). Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 3, 193–200.
    [Google Scholar]
  3. Bogger-Goren, S., Baba, K., Hurley, P., Yabuuchi, H., Takahashi, M. & Ogra, P. L. ( 1982; ). Antibody response in varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis 146, 260–265.[CrossRef]
    [Google Scholar]
  4. Bukreyev, A., Serra, M. E., Laham, F. R., Melendi, G. A., Kleeberger, S. R., Collins, P. L. & Polack, F. P. ( 2006; ). The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J Virol 80, 5854–5861.[CrossRef]
    [Google Scholar]
  5. Byrd, L. G. & Prince, G. A. ( 1997; ). Animal models of respiratory syncytial virus infection. Clin Infect Dis 25, 1363–1368.[CrossRef]
    [Google Scholar]
  6. Chen, M., Hu, K. F., Rozell, B., Orvell, C., Morcin, B. & Liljestrom, P. ( 2002; ). Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 169, 3208–3216.[CrossRef]
    [Google Scholar]
  7. Cohen, J. I., Straus, J. E. & Arvin, A. M. ( 2006; ). Varicella-zoster virus replication, pathogenesis and management. In Field's Virology, 5th edn, pp. 2774–2818. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Strauss. Philadelphia, PA: Lippincott, Williams & Wilkins.
  8. Collins, P. L. & Murphy, B. R. ( 2002; ). Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology 296, 204–211.[CrossRef]
    [Google Scholar]
  9. Connors, M., Kulkarni, A. B., Collins, P. L., Firestone, C. Y., Holmes, K. L., Morse, H. C., III & Murphy, B. R. ( 1992; ). Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 66, 1277–1281.
    [Google Scholar]
  10. Crowe, J. E. ( 1995; ). Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO programme for vaccine development. Vaccine 13, 415–421.[CrossRef]
    [Google Scholar]
  11. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. ( 2005; ). Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352, 1749–1759.[CrossRef]
    [Google Scholar]
  12. Fleming, D. M., Pannell, R. S. & Cross, K. W. ( 2005; ). Mortality in children from influenza and respiratory syncytial virus. J Epidemiol Community Health 59, 586–590.[CrossRef]
    [Google Scholar]
  13. Fletcher, T. M., III & Gray, W. L. ( 1992; ). Simian varicella virus: characterization of virion and infected cell polypeptides and the antigenic cross-reactivity with varicella-zoster virus. J Gen Virol 73, 1209–1215.[CrossRef]
    [Google Scholar]
  14. Fraticelli, P., Sironi, M., Bianchi, G., D'Ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M., Allavena, P., Ruco, L. & other authors ( 2001; ). Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107, 1173–1181.[CrossRef]
    [Google Scholar]
  15. Gershon, A. A., Steinberg, S. P., Gelb, L., Borkowsky, W., LaRussa, P. & Farrara, A. ( 1984; ). Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 252, 355–362.[CrossRef]
    [Google Scholar]
  16. Gevrey, J. C., Isaac, B. M. & Cox, D. ( 2005; ). Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (fractalkine). J Immunol 175, 3737–3745.[CrossRef]
    [Google Scholar]
  17. Glezen, W. P. ( 2004; ). The changing epidemiology of respiratory syncytial virus and influenza: impetus for new control measures. Pediatr Infect Dis J 23 (Suppl. 11), S202–S206.[CrossRef]
    [Google Scholar]
  18. Gray, W. L. ( 2003; ). Pathogenesis of simian varicella virus. J Med Virol 70, S4–S8.[CrossRef]
    [Google Scholar]
  19. Gray, W. L. ( 2004; ). Simian varicella: a model for human varicella-zoster virus infections. Rev Med Virol 14, 363–381.[CrossRef]
    [Google Scholar]
  20. Gray, W. L. & Mahalingam, R. ( 2005; ). A cosmid-based system for inserting mutations and foreign genes into the simian varicella virus genome. J Virol Methods 130, 89–94.[CrossRef]
    [Google Scholar]
  21. Gray, W. L., Williams, R. J., Chang, R. & Soike, K. F. ( 1998; ). Experimental simian varicella virus infection of St. Kitts vervet monkeys. J Med Primatol 27, 177–183.[CrossRef]
    [Google Scholar]
  22. Gray, W. L., Starnes, B., White, M. W. & Mahalingam, R. ( 2001; ). The DNA sequence of the simian varicella virus genome. Virology 284, 123–130.[CrossRef]
    [Google Scholar]
  23. Grose, C. ( 2005; ). Varicella vaccination of children in the United States: an assessment after the first decade 1995–2005. J Clin Virol 33, 89–98.[CrossRef]
    [Google Scholar]
  24. Harcourt, J., Alvarez, R., Jones, L. P., Henderson, C., Anderson, L. J. & Tripp, R. A. ( 2006; ). Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176, 1600–1608.[CrossRef]
    [Google Scholar]
  25. Heineman, T. C., Connelly, B. L., Bourne, N., Stanberry, L. R. & Cohen, J. ( 1995; ). Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 69, 8109–8113.
    [Google Scholar]
  26. Heineman, T. C., Pesnicak, L., Mir, A. A., Krogmann, T., Krudwig, N. & Cohen, J. I. ( 2004; ). Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. Vaccine 22, 2558–2565.[CrossRef]
    [Google Scholar]
  27. Jin, H., Cheng, X., Traina-Dorge, V., Park, H. J., Zhou, H., Soike, K. & Kemble, G. ( 2003; ). Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21, 3647–3652.[CrossRef]
    [Google Scholar]
  28. Johnson, T. R. & Graham, B. S. ( 1999; ). Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73, 8485–8495.
    [Google Scholar]
  29. Johnson, T. R., Johnson, J. E., Roberts, S. R., Wertz, G. W., Parker, R. A. & Graham, B. S. ( 1998; ). Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72, 2871–2880.
    [Google Scholar]
  30. Kamiyama, T., Sato, H., Takahara, T., Kageyama, S. & Shiraki, K. ( 2000; ). Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J Infect Dis 181, 1158–1161.[CrossRef]
    [Google Scholar]
  31. Levin, M. J., Gershon, A. A., Weinberg, A., Song, L. Y., Fentin, T. & Nowak, B., Pediatric AIDS Clinical Trial Group 265 Team ( 2006; ). Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4+ T cells. J Infect Dis 194, 247–255.[CrossRef]
    [Google Scholar]
  32. Maher, C. F., Hussell, T., Blair, E., Ring, C. J. A. & Openshaw, P. J. M. ( 2004; ). Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect 6, 1049–1055.[CrossRef]
    [Google Scholar]
  33. Olszewska, W., Suezer, Y., Sutter, G. & Openshaw, P. J. M. ( 2004; ). Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23, 215–221.[CrossRef]
    [Google Scholar]
  34. Openshaw, P. J. M. & Tregoning, J. S. ( 2005; ). Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev 18, 541–555.[CrossRef]
    [Google Scholar]
  35. Ou, Y., Traina-Dorge, V., Davis, K. A. & Gray, W. L. ( 2007; ). Recombinant simian varicella vaccines induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 364, 291–300.[CrossRef]
    [Google Scholar]
  36. Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S. & Gershon, A. A. ( 2005; ). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352, 2271–2284.[CrossRef]
    [Google Scholar]
  37. Patel, J. A., Nguyen, D. T., Revai, K. & Chonmaitree, T. ( 2007; ). Role of respiratory syncytial virus in acute otitis media: implications for vaccine and development. Vaccine 25, 1683–1689.[CrossRef]
    [Google Scholar]
  38. Phumiamorn, S., Sato, H., Kamiyama, T., Kurokawa, M. & Shiraki, K. ( 2003; ). Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine. J Gen Virol 84, 287–291.[CrossRef]
    [Google Scholar]
  39. Sasaki, K., Kato, M., Takahashi, T., Ochi, S., Ichinose, Y., Shiraki, K., Asano, Y., Iwanaga, M. & Tsuji, T. ( 2003; ). Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper cells with a single nasal coadministration in mice. J Med Virol 70, 329–335.[CrossRef]
    [Google Scholar]
  40. Shay, D. K., Holman, R. C., Roosevelt, G. E., Clarke, M. J. & Anderson, L. J. ( 2001; ). Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. J Infect Dis 183, 16–22.[CrossRef]
    [Google Scholar]
  41. Shiraki, K., Hayakawa, Y., Mori, H., Namazue, J., Takamizawa, A., Yoshida, I., Yamanishi, K. & Takahashi, M. ( 1991; ). Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol 72, 1393–1399.[CrossRef]
    [Google Scholar]
  42. Srikiatkhachorn, A. & Braciale, T. J. ( 1997; ). Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 186, 421–432.[CrossRef]
    [Google Scholar]
  43. Takimoto, T., Hurwitz, J. L., Coleclough, C., Prouser, C., Krishnamurthy, S., Zhan, X., Boyd, K., Scroggs, R. A., Brown, B. & other authors ( 2004; ). Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol 78, 6043–6047.[CrossRef]
    [Google Scholar]
  44. Terada, K., Niizuma, T., Ogita, S. & Kataoka, N. ( 2002; ). Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated vaccine. Vaccine 20, 3638–3643.[CrossRef]
    [Google Scholar]
  45. Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J. & Fukuda, K. ( 2003; ). Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179–186.[CrossRef]
    [Google Scholar]
  46. Tripp, R. A., Jones, L. P., Haynes, L. M., Zheng, H., Murphy, P. M. & Anderson, L. J. ( 2001; ). CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2, 732–738.[CrossRef]
    [Google Scholar]
  47. Van Drunen Littel-Van den Hurk, S., Mapletoft, J. W., Arsic, N. & Kovacs-Nolan, J. ( 2007; ). Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17, 5–34.[CrossRef]
    [Google Scholar]
  48. Wyatt, L. S., Whitehead, S. S., Venanzi, K. A., Murphy, B. R. & Moss, B. ( 1999; ). Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18, 392–397.[CrossRef]
    [Google Scholar]
  49. Yu, H. R., Chen, R. F., Hong, K. C., Bong, C. N., Lee, W. I., Kuo, H. C. & Yang, K. D. ( 2005; ). IL-12-independent Th1 polarization in human mononuclear cells infected with varicella-zoster virus. Eur J Immunol 35, 3664–3672.[CrossRef]
    [Google Scholar]
  50. Zambon, M. C., Stockton, J. D., Clewley, J. P. & Fleming, D. M. ( 2001; ). Contributions of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet 358, 1410–1416.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83453-0
Loading
/content/journal/jgv/10.1099/vir.0.83453-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error